The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known. ⋯ In this trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events. (Funded by Myovant Sciences; HERO ClinicalTrials.gov number, NCT03085095.).
-
Editorial Comparative Study
Audio Interview: Diagnosis and Early Treatment of Covid-19.